Analysis: Mike Kelly's sell of BMY (Bristol Myers Squibb Co)
Assessment: On watch
Rep. Mike Kelly's sale of BMY aligns with his Health subcommittee seat but is likely a routine portfolio rebalance, though massive research gaps warrant a cautious watchlist status.
- Member: Mike Kelly
- Party / state: R-PA (district 16)
- Chamber: House
- Transaction: Sell
- Amount: $15,001-$50,000
- Ticker: BMY
- Company: Bristol Myers Squibb Co
- Trade date: 2026-05-07
- Disclosure date: 2026-06-11
- Disclosure lag: 35 days
Executive summary
This research packet covers Rep. Mike Kelly’s sale of Bristol Myers Squibb (BMY) on 2026-05-07 (self; $15,001-$50,000), disclosed on 2026-06-11 (35-day lag). The only same-day related activity in the provided history is a smaller sale of CMCSA on the same date. SEC EDGAR context available in the input shows BMY filed an earnings-related 8-K on 2026-04-30 and a vote-results 8-K on 2026-05-08; no 10-K extraction could be completed here due to access constraints.
From the user-provided trading history, the member has 15 total trades across 14 tickers (2024-03-28 to 2026-05-07), with most tickers appearing only once; BMY appears only once and only as a sale (no prior BMY purchases in the provided dataset). The analyzed BMY sale occurred the same day as a CMCSA sale, which is consistent with a batch of sales activity on 2026-05-07 rather than an isolated single-ticker action (directionally both are sells; BMY is the larger disclosed range). Issuer-side events available from the provided SEC enrichment show an earnings/results-related 8-K filed 2026-04-30 (Items 2.02/7.01/9.01) and an Item 5.07 vote-related 8-K filed 2026-05-08 (earliest event 2026-05-05), bracketing the 2026-05-07 trade date. Insider Forms 4 in the provided window include derivative exercises/conversions and tax-withholding transactions (codes M and F), which are reported but not identified as open-market buys/sells in the provided data. Broader legislative/regulatory/contracting context could not be gathered due to lack of access to Congress.gov, Federal Register, Regulations.gov, and USAspending.gov from this environment.
Timeline
- 2026-04-30 — Bristol Myers Squibb filed an 8-K reporting Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits).
- 2026-04-30 — Exhibit 99.1 press release attached to 8-K dated April 30, 2026 (first quarter 2026 results).
- 2026-05-01 — Form 4 transactions reported for Adam Lenkowsky (EVP, Chief Commercial Officer), including code M (derivative exercise/conversion), code F (tax withholding/payment), and code J.
- 2026-05-07 — Rep. Mike Kelly sold BMY in the amount range $15,001-$50,000 (self).
- 2026-05-07 — Same-day portfolio activity: Rep. Mike Kelly sold CMCSA in the amount range $1,001-$15,000 (self).
- 2026-05-08 — Bristol Myers Squibb filed an 8-K reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Date of earliest event reported: May 5, 2026.
- 2026-06-03 — Form 4 transactions reported for Wendy Bartie Short (EVP, Corporate Affairs), including code M (derivative exercise/conversion) and code F (tax withholding/payment).
- 2026-06-11 — Rep. Mike Kelly disclosed the 2026-05-07 BMY sale (filed 2026-06-11).
Independent analysis of public financial disclosures. Not financial or investment advice.